Pansoral (Choline Salicylate, Cetalkonium Chloride)

Choline salicylate belongs to the non‑steroidal anti‑inflammatory drug (NSAID) class. It blocks cyclooxygenase enzymes, which reduces the synthesis of prostaglandins—key mediators of pain, swelling and fever—thereby providing analgesic and anti‑inflammatory effects at the site of application.

The appropriate dose of Pansoral is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms and overall health status. Patients should follow the prescriber’s instructions and the product label without exceeding the recommended frequency.

Safety data for Pansoral in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should consult their physician before using the product to weigh potential benefits against any unknown risks.

To order Pansoral, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike many lozenges that contain only a single analgesic, Pansoral combines an NSAID (choline salicylate) with an antiseptic (cetalkonium chloride). This dual action offers both pain relief and antimicrobial activity, which can be advantageous when a sore throat is accompanied by mild infection.

Pansoral should be stored at ambient temperature below 25 °C, in its original packaging, and protected from moisture. Keep the product out of reach of children and avoid exposing it to direct sunlight or extreme humidity.

Pansoral is taken orally, typically as a lozenge or dissolved tablet, allowing the active ingredients to act directly on the oral mucosa. Patients should allow the product to dissolve slowly in the mouth and avoid swallowing whole tablets before they have dissolved.

Serious adverse reactions, although rare, include severe allergic responses such as rash, swelling, or difficulty breathing, and gastrointestinal bleeding. If any signs of a severe reaction appear, the user should stop the product immediately and seek medical attention.

Individuals with a known hypersensitivity to salicylates, cetalkonium chloride, or any component of the formulation should avoid Pansoral. It is also contraindicated in patients taking anticoagulant therapy, other NSAIDs, or those with active gastrointestinal ulceration unless directed by a physician.